The global Breast Biopsy Market was calculated at USD 1129 million in 2021 and is estimated to reach USD 1992 million by 2028, growing at a CAGR of 5.6% during the forecast period of 2022 to 2028. The increase in awareness regarding early detection of breast cancer and the improved reimbursement scheme further influence the market growth. Further, the rise in population, surge in healthcare expenditure and rise in endeavors by public organizations towards female health problems thoroughly affect the breast biopsy devices market.
A breast biopsy is a test conducted to extract tissue or fluid from a diseased place of the patient’s body, while the extracted sample is further analyzed to check the presence of breast cancer. There are different types of biopsy methods depending on the product, such as vacuum-assisted biopsy, core needle biopsy, and fine-needle aspiration biopsy, recommended by the doctor based on location and size and different elements of the breast irregularity. The different methods of the biopsy market work fast, and it is easy. As a result, the results are fast and correct.
Breast cancer is among the familiar diseases in progressive and developing countries. According to the American Cancer Society, breast cancer is the second-leading reason of cancer-related deaths worldwide. For example: In the US, one in eight women creates invasive breast cancer for her lifetime. According to the American Cancer Society and the National Cancer Institute, in 2018, over 265,000 new patients with invasive breast cancer were diagnosed among women in the US, with 63,960 new cases of non-invasive breast cancer. In Canada, as many as 26,300 women were diagnosed with breast cancer in 2017, expressing 25% of new cancer cases (Source: Canadian Cancer Society), i.e., 72 Canadian women are diagnosed with breast cancer every day.
The increasing number of breast cancer patients has caused governments across the globe to increase awareness regarding the implication of early detection of breast cancer, which is expected to drive market growth.
Liquid biopsy is a blood test that aids physicians in determining cancer cells or DNA elements of tumors in blood. This technique stops the need to carry out surgical and needle biopsies and allows physicians to identify cancer in the early stages. It also catches the full genetic complexity of tumors and limits the chances of cancer cells chances to spread to other parts of the body. Currently, different players are conducting clinical trials to establish the usefulness and efficiency of liquid biopsy in oncology; the favorable results are anticipated to create new opportunities for players operating in the market.
Biopsy needle methods, such as core and fine needle procedures, help radiologists and surgeons examine irregularities at a particular site. However, patients can contract infections during these processes, involving cuts and incisions to remove tissue samples. In several cases, biopsy needles are reused, increasing the chance of infection during these procedures. While healthcare management and product manufacturers do not advise the reuse of some needles, the practice is still prevalent, especially in developing countries.
Thus, to avoid the chance of infections from these methods, healthcare providers and patients may opt for alternative diagnostic methods for target situations.
Before the covid-19 outbreak, Novel biopsy methods and the beginning of new product approvals provides minimally invasive procedures. A 6mm Bergstrom side-cutting biopsy needle was believed a successful instrument to obtain large pieces of tissue under the guidance of ultrasound. Such new instruments and techniques have seriously affected the overall growth of the Breast biopsy market. In recent years, increasing incidences of breast cancer have been the primary growth attributing factor for the Breast biopsy market. Over 265,000 cancer susceptive cases were diagnosed in 2018 and assumed out over 63,960 non-invasive methods during the year. Such reports stimulate the overall growth of the market.
During the covid-19 period, the impact of the pandemic and the lockdown it started is visible in various industries, including the breast biopsy market. The execution of new guidelines and restrictions is hindering the growth of this industry. Moreover, restricted access to clinics, social distancing, the lockdown of the population, which results in a slow-down in patient flow and referrals, has also affected the market growth.
After the covid-19 period, the recommendation for breast biopsy, especially the mammography-guided stereotactic biopsy, has rapidly expanded the adoption rate in developed countries. Moreover, the rationalizing usage of mammography complemented by the other breast examinations has helped as a pillar for screening breast cancer-driving the market growth.
The market is segmented into Needles, Tables, and Assay Kit based on product segmental analysis. The biopsy needle segment held a major share of the market. The biopsy needles segment is anticipated to hold a major share of the breast biopsy market due to the rising adoption of image-guided techniques in developed and developing countries and the introduction of technologically advanced and novel designs. For example, the tri-axial needle is composed of a pincer needle on the outer side, an outer cutting needle, and a sharp stylet on the inner side.
Based on type segmental analysis, the market is segmented into Needle Biopsy {CNB, FNAB, VAB}, Liquid Biopsy {CTC, ctDNA}, and Guidance {Image-Guided {Mammography, Liquid Biopsy}}. The liquid biopsy segment is expected to record the highest growth over the forecast period of 2021-2028. Liquid biopsy has arisen as a revolutionary technology that delivers new sizes to oncology diagnostics. The significant growth of the segment is attributed to the growing adoption of novel NGS-based assays and droplet digital PCR technology to serve liquid biopsies in most developed countries.
Based on the end-user segmental analysis, the market is segmented into Hospitals and Diagnostic Centers. Hospitals are undertaking novel endeavors to raise public awareness about breast cancer and the clinical benefits of its early diagnosis through screening programs. These initiatives to increase awareness about early detection and diagnosis of breast cancer will fuel the demand for breast biopsy systems, further driving market growth in the hospital segment.
Based on the regional segmental analysis, the market is segmented into North America, Europe, Asia-Pacific, South America and The Middle East & Africa. Asia Pacific region market to record the highest growth for the breast biopsy market. The healthcare infrastructure in rising economies such as China, India, and South Korea is growing fast, offering major investments in developed systems (including liquid breast biopsy and vacuum-assisted biopsy instruments, among others) by hospitals and breast care centers.
The companies include Hologic Inc., Leica Biosystems Nussloch GmbH, C.R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC, Intact Medical Corporation, Galini SRL and other prominent players in the global breast biopsy market.
Key Stakeholders
| Report Attribute | Details |
|---|---|
| Market Size Value in 2021 | USD 1129 million |
| The revenue forecast in 2028 | USD 1992 million |
| Growth Rate | CAGR of 5.6% from 2022 to 2028. |
| Historical data | 2017 – 2020 |
| Base Year | 2021 |
| Forecast period | 2022 – 2028 |
| Region covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Key companies Profiled | The Companies include Hologic Inc., Leica Biosystems Nussloch GmbH, C.R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC, Intact Medical Corporation, Galini SRL are the key players. |
By Product
By Type
By End-User
By Region
The global Breast Biopsy Market was calculated at USD 1129 million in 2021 and is estimated to reach USD 1992 million by 2028, growing at a CAGR of 5.6% during the forecast period of 2022 to 2028.
Liquid biopsy is a blood test that aids physicians in determining cancer cells or DNA elements of tumors in blood. This technique stops the need to carry out surgical and needle biopsies and allows physicians to identify cancer in the early stages. It also catches the full genetic complexity of tumors and limits the chances of cancer cells chances to spread to other parts of the body. Currently, different players are conducting clinical trials to establish the usefulness and efficiency of liquid biopsy in oncology; the favorable results are anticipated to create new opportunities for players operating in the market.
Patients can contract infections during these processes involving cuts and incisions to remove tissue samples. In several cases, biopsy needles are reused, increasing the chance of infection during these procedures.
The companies include Hologic Inc., Leica Biosystems Nussloch GmbH, C.R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC, Intact Medical Corporation, Galini SRL and other prominent players in the global breast biopsy market.
Asia Pacific region market to record the highest growth for the breast biopsy market.
Analyst support
After evaluating your requirements and addressing your technical problems, the expert analyst will resolve your query directly.
Customer satisfaction
According to your needs, our expert team will assist you with the capabilities, services, and proper research needs to be required and customize the report accordingly.
Inimitable expertise
Our expert team will create unrivaled reviews to provide you with a deep understanding of the reports.
Assured quality
We have created a systematic way to determine standards and satisfy your expectations.
Instant delivery
Unlike others, we provide you a great deal of instant delivery in the form of PDF/PPT/Word Doc directly to your email address within 24 hours after receiving full payment.
Privacy policy
We understand the inkling of your privacy, we will never misuse your email address.
Custom research service
We are giving you an opportunity through which you can directly ask our expert analyst to customize an exclusive study of the report to serve your research needs.
Quality & accuracy
We provide you with the accurate quality of the customized study of an exclusive report according to your research need.
Data visualization
As the business world’s growing faster every day, we understand the value of data management. We will create the reports by keeping all the visual data sets and metrics in the charts.
Information security
We truly respect your privacy and promise to keep your personal and confidential information safe and secure.